


Next-generation vaccines from the experts.

A global partner in the discovery, design, and development of viral, bacterial, and conjugate vaccines.



Intravacc at a glance



100+

Highly qualified employees



100+

Years of experience



300+

Scientific publications in
peer-reviewed journals



50+

Customers worldwide



>2,000 m²

State-of-the-art facilities




11

Patent families

Innovating vaccines.

Intravacc is a customer-focused, global CDMO for therapeutic and infectious disease vaccines. With over 100 years of experience in the development and optimization of vaccines and vaccine technologies, Intravacc has transferred its knowledge and technology to biotech and pharmaceutical companies, governmental

agencies, and NGOs around the world. That expertise, combined with our proprietary vaccine platforms and state-of-the-art Good Manufacturing Practices (GMP) facilities, positions us at the forefront of advancements in both human and veterinary vaccine and immunotherapy spaces.



Our CDMO Services at a glance.

Discovery and production


- **Vaccine strain design, modification, and optimization**
 - Bacterial strain construction
 - Viral strain construction and rescue
- **Process development**
 - Cell banking
 - Seed lot production
 - Scale-up
 - Formulation
- **Pre-clinical characterization**
- **GMP manufacturing, 1-200 liters**

Characterization

- **Physicochemical**
 - Content
 - Higher-order structure
 - Antigenicity
 - Impurities
 - Excipient
 - Stability
- **Immunological**
 - Innate assays
 - Humoral assays
 - Cellular assays

Stellar track record

- 2 OMV vaccines out-licensed
- 1 conjugate AMR vaccine out-licensed and marketed
- 1 cell-based viral vaccine out-licensed and marketed
- 300+ scientific publications
- 50+ customers worldwide
- 10+ partnerships



Scale-up


Analytical method validation

Stability studies


Technology transfer




Our proprietary vaccine development platforms.




OMV-Vacc Technology
Outer Membrane Vesicles
Highly versatile platform with a wide range of applications for prophylactic and therapeutic vaccines.



Cell-Vacc Technology
Vero cells
Globally used for routine, large-scale commercial vaccine manufacturing.



Con-Vacc Technology
Conjugation
Twenty-year track record in designing, developing, and characterizing conjugate vaccines.



E.co-Vacc Technology
***E. coli* expression system**
Versatile protein expression platform for oncology, infectious diseases, and other applications.

Our unique pipeline of Avacc[®] vaccine candidates, open for licensing.

Pipeline	Vaccine	Target	Technology	Development stage		
				Discovery	Pre-clinical	Clinical phase I
Licensed out/open for licensing in certain regions	Avacc 3	Pertussis	OMV-Vacc			
	Avacc 13	MenB	OMV-Vacc			
Open for licensing	Avacc 2	HFMD	Cell-Vacc			
	Avacc 5	EV D68	Cell-Vacc			
	Avacc 10	COVID-19	OMV-Vacc			
	Avacc 11	Gonorrhea	OMV-Vacc			
	Avacc 12	Gonorrhea	OMV-Vacc			
	Avacc 31	ALS	Con-Vacc			

Avacc 2 HFMD

- First-in-class quadrivalent vaccine
- Induces high antibody titers
- GMP seed lots produced for 3 strains

Avacc 3 Pertussis

- Broad protection
- Good safety profile
- Out-licensed for further development in certain regions

Avacc 5 EV D68

- Induces high virus neutralizing titers
- GMP seed lot produced
- Pre-clinical studies in 2024

Avacc 10 COVID-19

- Intranasal vaccine
- Excellent pre-clinical data
- Phase I clinical trial in progress

Avacc 11 Gonorrhea

- First-in-class intranasal vaccine
- Effective in animal models
- Co-developed with Therapyx, Inc.

Avacc 12 Gonorrhea

- Proprietary heterologous OMV technology
- Elicits IgG response in pre-clinical studies

Avacc 13 MenB

- Nonavalent PorA vaccine
- Excellent pre-clinical data
- Out-licensed for further development in certain regions

Avacc 31 ALS

- Conjugate vaccine
- Prophylactic and therapeutic
- Co-developed with the German Center for Neurodegenerative Diseases (DZNE)

Learn more

Are you interested in our CDMO services, vaccine development platforms, or pipeline of vaccine candidates? Our Business Development team is happy to discuss all possibilities with you.

Get in touch!

email us at: bd@intravacc.nl

Disclaimer: Intravacc assumes no liability or responsibility for any errors or omissions in the information included in this brochure, including forward looking statements. The information is provided "as is" with no guarantees of completeness, accuracy, or timeliness, and without warranties of any kind, expressed or implied.

Avacc is a registered trademark of Intravacc B.V. Copyright © 2024 Intravacc. All rights reserved.

Intravacc B.V. Utrecht Science Park Bilthoven . Antonie van Leeuwenhoeklaan 9 . 3721 MA Bilthoven . The Netherlands
 Phone: +31 30 792 03 00 . Mail: bd@intravacc.nl ————— intravacc.nl

